Open company graph database — free web & API
Login

PDR Pharma Inc.

PDRファーマ株式会社PDRadiopharma Inc.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
7
§01

Basic information

BASIC
Head office
2-14-1 Kyobashi, Chuo-ku, Tokyo 104-0031, Kenmatsu Building
Chief executive
Masato Murakami
Capital
100,000,000
Employees (non-consolidated)
Employees (consolidated)
Start date
2022-03-28
End date
§02

Websites

1 DOMAINS
§03

Business

4
Manufacturing and supply of radiopharmaceuticalsTotal solutions for RI diagnosis and RI therapyResearch, development, manufacturing, sales, export, and import of radiopharmaceuticals and related productsAdministration devices, image analysis software, and medical DX
§04

Related companies

7 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Curiumグループ
ペプチドリームグループ
PeptiDream Inc.
Fujifilm RI Pharma Co., Ltd.
富山化学工業株式会社
第一製薬グループ
米国マリンクロット社
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

9 EVENTS

Established Daiichi Radioisotope Research Institute Co., Ltd. as a joint venture between Daiichi Pharmaceutical Group and Marinklot Inc. (USA).Sources

Completion of Chiba plant (relocated to Matsuo-cho, Yamate-gun, Chiba Prefecture).Sources

Dissolution of joint venture with Marinklot Inc. (USA) – Daiichi Pharmaceutical became 100% subsidiary.Sources

Transfer of all shares from Daiichi Pharmaceutical Co., Ltd. to Fujifilm Co., Ltd. (Fujifilm became 100% subsidiary).Sources

Renamed to Fujifilm RI Pharma Co., Ltd.Sources

Established Kawasaki / Ibaraki PET labs.Sources

Established Kawasaki Lab / Ibaraki Lab.Sources

Merged with Toyama Chemical Industries Co., Ltd. and renamed to Fujifilm Toyama Chemical Co., Ltd.Sources

Acquired the radiopharmaceutical business of Fujifilm Toyama Chemical Co., Ltd. through a carve-out and commenced operations as PDR Pharma Inc. (100% subsidiary of Peptide Dream Co., Ltd.).Sources

§07

News

14 ARTICLES

Deputy Minister Suzuki and Governor Kumagai of Chiba Prefecture Inspect Chiba FactorySources

Deputy Minister for Internal Affairs and Communications Suzuki Eikei and Deputy Minister for the Cabinet Office, and Governor Kumagai Toshihito of Chiba Prefecture inspected the PDR Pharma Chiba factory as part of forming regional industry clusters in drug discovery, advanced medicine, and biotechnology. The inspection is featured in the "Latest Update on PDR Pharma" section of the PeptiDream Quarterly Newsletter issued by the parent company Peptide Dream Co., Ltd.

Response to PHP Vulnerability on Our Company-Operated SiteSources

Our company has completed the update of PHP used in part of our operating site, including the homepage, to address the vulnerability. We will continue to work on ongoing security measures.

Lecture at the 64th Japanese Society of Cancer Therapy Academic ConferenceSources

PDR Pharma will deliver a lecture at the 64th Japanese Society of Cancer Therapy Academic Conference, held from October 22 to 24, 2026. President and CEO Masato Murakami will discuss the theme "Implementing targeted alpha particle therapy for patients," outlining the challenges and initiatives toward ensuring stable delivery to patients.

Speaking Engagement at ESRAH2026Sources

PDR Pharma will speak at the 13th Educational Symposium on Radiation and Health by Young Scientists (ESRAH2026). President and Representative Director Masato Murakami will present on “Building the Future of Radiopharmaceuticals: Peptide Discovery, Theranostics and Translation to Patient Care.” The presentation will promote collaboration and exchange of insights with young researchers to advance radiopharmaceuticals.

PDR Pharma to Give Nuclear Medicine Talks in NagasakiSources

At PET Summer Seminar 2026 in Nagasaki, PDR Pharma President and CEO Masato Murakami and Hiroshi Sugihara of the Product Strategy Department will give presentations. Murakami will discuss strategies for implementing nuclear medicine in society, while Sugihara will address risk management for a stable supply of PET radiopharmaceuticals. Both talks focus on the future of nuclear medicine and its contribution to healthcare.

PDR Pharma President Publishes Article in Accelerator JournalSources

President Masato Murakami contributed an article titled 'From Accelerators to the Bedside: Next-Generation Medicine Created by Radiopharmaceuticals' to Accelerator, the journal of the Particle Accelerator Society of Japan. The article discusses the radiopharmaceutical value chain and collaboration among industry, government, academia, and healthcare. PDR Pharma works to expand diagnostic and treatment options for patients through radiopharmaceutical research, development, and supply.

PeptiDream CEO Patrick Reid Featured in Nikkei Business TODAYSources

In an interview with Nikkei’s Business TODAY, PeptiDream CEO Patrick Reid discussed the company’s growth strategy and outlook for its radiopharmaceutical business. He aims to contribute to medical progress and deliver new value to patients through radiopharmaceuticals.

PDR Pharma President Appointed Chair of Japan Radioisotope AssociationSources

Masato Murakami became chair of the Japan Radioisotope Association on June 19, 2026. The association promotes the safe handling of radiopharmaceuticals and transport safety. PDR Pharma participates in its activities and aims to contribute to the industry's development and to healthcare.

PDR Pharma President to Speak at CPHI Japan 2026Sources

PDR Pharma President Masato Murakami will speak at the drug discovery symposium at CPHI Japan 2026, held at Tokyo Big Sight on April 21, 2026. His talk will focus on peptide drug discovery and radiopharmaceuticals, discussing the importance of an ecosystem and integrated approaches to strengthen Japan's drug discovery capabilities.

PDR Pharma President Joins Expert Panel on RadiopharmaceuticalsSources

PDR Pharma President Masato Murakami joined an expert panel focused on developing, manufacturing, and promoting the use of radiopharmaceuticals. The panel will discuss strengthening the radiopharmaceutical supply chain. Murakami will contribute perspectives from industry, including the company's research and development efforts.

§08

Public records

GOV
National Tax Agency basic information6010001219863
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
PDRファーマ株式会社
Trade name (kana)
ピーディーアールファーマ
Name in English
Corporation type
301
Address
〒104-0031 東京都中央区京橋2丁目14番1号
Postal code
1040031
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2021-07-21
Update date
2021-10-13
Change date
2021-10-11
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
11
Correction type
0
Trade name image ID
Address image ID
Sequence number
2025768
METI gBizINFO6010001219863
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6010001219863
Trade name
PDRファーマ株式会社
Trade name (kana)
ピーディーアールファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区京橋2丁目14番1号
Postal code
1040031
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
京橋2丁目14番1号
Organisation type
301
Processing type
11
Correction type
0
Status
Representative
Capital
Employees
476
Employees (male)
378
Employees (female)
98
Business summary
Website URL
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2021-10-13
Key information
6010001219863
§09

Sources & updates

SOURCES
↑